A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.

doi:10.1158/1078-0432.CCR-17-2815

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2018

Liu Xiaoyan, Swen Jesse J, Diekstra Meta H M, Boven Epie, Castellano Daniel, Gelderblom Hans, Mathijssen Ron H J, Vermeulen Sita H, Oosterwijk Egbert, Junker Kerstin, Roessler Max, Alexiusdottir Kristin, Sverrisdottir Asgerdur, Radu Marius T, Ambert Valentin, Eisen Tim, Warren Anne, Rodríguez-Antona Cristina, García-Donas Jesus, Böhringer Stefan, Koudijs Karel K M, Kiemeney Lambertus A L M, Rini Brian I, Guchelaar Henk-Jan

Abstract excerpt

Purpose: The survival of patients with clear cell metastatic renal cell carcinoma (cc-mRCC) has improved substantially since the introduction of tyrosine kinase inhibitors (TKI). With the fact that TKIs interact with immune responses, we investigated whether polymorphisms of genes involved in immune checkpoints are related to the clinical outcome of cc-mRCC patients treated with sunitinib as first...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Renal Cell

Share to CTLA-4 Antigen

Share to Proportional Hazards Models

Share to Protein Kinase Inhibitors

Share to Sunitinib

Share to Survival Analysis

Source

Open in PubMed

Identifiers

PMID: 29490989
DOI: 10.1158/1078-0432.CCR-17-2815

Genes

PDCD1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.PMID 29490989Read ↗

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.Semantic proximity Read ↗

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.Semantic proximity Read ↗

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.Semantic proximity Read ↗

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.Semantic proximity Read ↗

Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.Semantic proximity Read ↗

Association Between Polymorphisms in Genes Encoding PD-1/PD-L1 Molecules and Clinicopathological Features in Clear Cell Renal Cell Carcinoma.Semantic proximity Read ↗

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.Semantic proximity Read ↗

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.Semantic proximity Read ↗

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.Semantic proximity Read ↗

Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with SorafenibSemantic proximity Read ↗

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.Semantic proximity Read ↗

Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.